|
1
|
Dawkins J and Webster RM: The
hepatocellular carcinoma market. Nat Rev Drug Discov. 18:13–14.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ryerson AB, Eheman CR, Altekruse SF, Ward
JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM,
et al: Annual report to the nation on the status of cancer,
1975–2012, featuring the increasing incidence of liver cancer.
Cancer. 122:1312–1337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nikolaou K, Sarris M and Talianidis I:
Molecular pathways: The complex roles of inflammation pathways in
the development and treatment of liver cancer. Clin Cancer Res.
19:2810–2816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arzumanyan A, Reis HM and Feitelson MA:
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular
carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Solinas G, Germano G, Mantovani A and
Allavena P: Tumor-associated macrophages (TAM) as major players of
the cancer-related inflammation. J Leukoc Biol. 86:1065–1073. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Boniakowski AE, Kimball AS, Jacobs BN,
Kunkel SL and Gallagher KA: Macrophage-mediated inflammation in
normal and diabetic wound healing. J Immunol. 199:17–24. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Glass CK and Natoli G: Molecular control
of activation and priming in macrophages. Nat Immunol. 17:26–33.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Binnemars-Postma K, Storm G and Prakash J:
Nanomedicine strategies to target tumor-associated macrophages. Int
J Mol Sci. 18:9792017. View Article : Google Scholar
|
|
14
|
Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li
CX, Ng KT, Forbes SJ, Guan XY, Poon RT, et al: Alternatively
activated (M2) macrophages promote tumour growth and invasiveness
in hepatocellular carcinoma. J Hepatol. 62:607–616. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Capece D, Fischietti M, Verzella D,
Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F and Alesse E:
The inflammatory microenvironment in hepatocellular carcinoma: A
pivotal role for tumor-associated macrophages. Biomed Res Int.
2013:1872042013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharif O and Knapp S: From expression to
signaling: Roles of TREM-1 and TREM-2 in innate immunity and
bacterial infection. Immunobiology. 213:701–713. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tessarz AS and Cerwenka A: The
TREM-1/DAP12 pathway. Immunol Lett. 116:111–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Read CB, Kuijper JL, Hjorth SA, Heipel MD,
Tang X, Fleetwood AJ, Dantzler JL, Grell SN, Kastrup J, Wang C, et
al: Cutting edge: Identification of neutrophil PGLYRP1 as a ligand
for TREM-1. J Immunol. 194:1417–1421. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Bremen T, Dromann D, Luitjens K, Dodt
C, Dalhoff K, Goldmann T and Schaaf B: Triggering receptor
expressed on myeloid cells-1 (Trem-1) on blood neutrophils is
associated with cytokine inducibility in human E. coli
sepsis. Diagn Pathol. 8:242013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ho CC, Liao WY, Wang CY, Lu YH, Huang HY,
Chen HY, Chan WK, Chen HW and Yang PC: TREM-1 expression in
tumor-associated macrophages and clinical outcome in lung cancer.
Am J Respir Crit Care Med. 177:763–770. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen ZT and Sigalov AB: Novel TREM-1
inhibitors attenuate tumor growth and prolong survival in
experimental pancreatic cancer. Mol Pharm. 14:4572–4582. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu J, Li J, Salcedo R, Mivechi NF,
Trinchieri G and Horuzsko A: The proinflammatory myeloid cell
receptor TREM-1 controls Kupffer cell activation and development of
hepatocellular carcinoma. Cancer Res. 72:3977–3986. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tandon P, Abraldes JG, Keough A,
Bastiampillai R, Jayakumar S, Carbonneau M, Wong E, Kao D, Bain VG
and Ma M: Risk of bacterial infection in patients with cirrhosis
and acute variceal hemorrhage, based on Child-Pugh class, and
effects of antibiotics. Clin Gastroenterol Hepatol.
13:1189–1196.e2. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Genin M, Clement F, Fattaccioli A, Raes M
and Michiels C: M1 and M2 macrophages derived from THP-1 cells
differentially modulate the response of cancer cells to etoposide.
BMC Cancer. 15:5772015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T). Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Wang JN, Tang JM, Kong X, Yang
JY, Zheng F, Guo LY, Huang YZ, Zhang L, Tian L, et al: VEGF is
essential for the growth and migration of human hepatocellular
carcinoma cells. Mol Biol Rep. 39:5085–5093. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Polyak K, Haviv I and Campbell IG:
Co-evolution of tumor cells and their microenvironment. Trends
Genet. 25:30–38. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Condeelis J and Pollard JW: Macrophages:
Obligate partners for tumor cell migration, invasion, and
metastasis. Cell. 124:263–266. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bouchon A, Dietrich J and Colonna M:
Cutting edge: Inflammatory responses can be triggered by TREM-1, a
novel receptor expressed on neutrophils and monocytes. J Immunol.
164:4991–4995. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Duan M, Wang ZC, Wang XY, Shi JY, Yang LX,
Ding ZB, Gao Q, Zhou J and Fan J: TREM-1, an inflammatory
modulator, is expressed in hepatocellular carcinoma cells and
significantly promotes tumor progression. Ann Surg Oncol.
22:3121–3129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liao R, Sun TW, Yi Y, Wu H, Li YW, Wang
JX, Zhou J, Shi YH, Cheng YF, Qiu SJ and Fan J: Expression of
TREM-1 in hepatic stellate cells and prognostic value in hepatitis
B-related hepatocellular carcinoma. Cancer Sci. 103:984–992. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Colegio OR, Chu NQ, Szabo AL, Chu T,
Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC,
Phillips GM, et al: Functional polarization of tumour-associated
macrophages by tumour-derived lactic acid. Nature. 513:559–563.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lo TH, Tseng KY, Tsao WS, Yang CY, Hsieh
SL, Chiu AW, Takai T, Mak TW, Tarng DC and Chen NJ: TREM-1
regulates macrophage polarization in ureteral obstruction. Kidney
Int. 86:1174–1186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ye Y, Xu Y, Lai Y, He W, Li Y, Wang R, Luo
X, Chen R and Chen T: Long non-coding RNA cox-2 prevents immune
evasion and metastasis of hepatocellular carcinoma by altering
M1/M2 macrophage polarization. J Cell Biochem. 119:2951–2963. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guillermet-Guibert J, Bjorklof K, Salpekar
A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K
and Vanhaesebroeck B: The p110beta isoform of phosphoinositide
3-kinase signals downstream of G protein-coupled receptors and is
functionally redundant with p110gamma. Proc Natl Acad Sci USA.
105:8292–8297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vergadi E, Ieronymaki E, Lyroni K,
Vaporidi K and Tsatsanis C: Akt signaling pathway in macrophage
activation and M1/M2 polarization. J Immunol. 198:1006–1014. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Byles V, Covarrubias AJ, Ben-Sahra I,
Lamming DW, Sabatini DM, Manning BD and Horng T: The TSC-mTOR
pathway regulates macrophage polarization. Nat Commun. 4:28342013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rauh MJ, Ho V, Pereira C, Sham A, Sly LM,
Lam V, Huxham L, Minchinton AI, Mui A and Krystal G: SHIP represses
the generation of alternatively activated macrophages. Immunity.
23:361–374. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ruckerl D, Jenkins SJ, Laqtom NN,
Gallagher IJ, Sutherland TE, Duncan S, Buck AH and Allen JE:
Induction of IL-4Rα-dependent microRNAs identifies PI3K/Akt
signaling as essential for IL-4-driven murine macrophage
proliferation in vivo. Blood. 120:2307–2316. 2012. View Article : Google Scholar : PubMed/NCBI
|
